Johnson & Johnson is cutting several programs—most of which are in neurology and psychiatry—as the company also pulls back from the infectious diseases market.
Centessa Pharmaceuticals plc recently detailed the discovery and preclinical characterization of a novel potent and selective orexin OX2 receptor agonist, ORX-142.
Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, ...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary ...
The stock is up 6.6% premarket. “Following interim ORX750 Phase 1 results, we see a clear path for Phase 2 development and believe orexin 2 is further de risked as a mechanism for treating ...